MORANDI, ANDREA
 Distribuzione geografica
Continente #
NA - Nord America 3.681
EU - Europa 2.952
AS - Asia 1.895
SA - Sud America 300
AF - Africa 41
OC - Oceania 18
Continente sconosciuto - Info sul continente non disponibili 1
Totale 8.888
Nazione #
US - Stati Uniti d'America 3.650
PL - Polonia 1.043
RU - Federazione Russa 889
SG - Singapore 589
CN - Cina 503
IT - Italia 412
HK - Hong Kong 326
BR - Brasile 238
KR - Corea 177
IE - Irlanda 156
SE - Svezia 141
VN - Vietnam 123
DE - Germania 62
FR - Francia 49
FI - Finlandia 43
GB - Regno Unito 40
ID - Indonesia 36
IN - India 36
ES - Italia 33
NL - Olanda 27
JO - Giordania 26
AR - Argentina 22
AU - Australia 17
EC - Ecuador 16
UA - Ucraina 16
CH - Svizzera 12
ZA - Sudafrica 12
BD - Bangladesh 11
BE - Belgio 11
CI - Costa d'Avorio 11
MX - Messico 11
TR - Turchia 11
CA - Canada 10
AE - Emirati Arabi Uniti 9
JP - Giappone 8
IQ - Iraq 7
CL - Cile 5
CO - Colombia 5
MA - Marocco 5
TW - Taiwan 5
UY - Uruguay 5
AT - Austria 4
BJ - Benin 4
GR - Grecia 4
MY - Malesia 4
PY - Paraguay 4
AZ - Azerbaigian 3
EG - Egitto 3
IL - Israele 3
PA - Panama 3
PK - Pakistan 3
VE - Venezuela 3
CR - Costa Rica 2
CZ - Repubblica Ceca 2
DK - Danimarca 2
DZ - Algeria 2
KE - Kenya 2
LB - Libano 2
NP - Nepal 2
PT - Portogallo 2
SA - Arabia Saudita 2
TT - Trinidad e Tobago 2
AL - Albania 1
BG - Bulgaria 1
BO - Bolivia 1
CY - Cipro 1
EU - Europa 1
GL - Groenlandia 1
GT - Guatemala 1
KG - Kirghizistan 1
KI - Kiribati 1
KW - Kuwait 1
KZ - Kazakistan 1
LT - Lituania 1
LV - Lettonia 1
MM - Myanmar 1
NG - Nigeria 1
NI - Nicaragua 1
PE - Perù 1
PH - Filippine 1
QA - Qatar 1
SN - Senegal 1
TH - Thailandia 1
UZ - Uzbekistan 1
Totale 8.888
Città #
Warsaw 1.039
Santa Clara 836
Fairfield 453
Singapore 430
Ashburn 391
Hong Kong 289
Woodbridge 198
Houston 186
Seattle 186
Seoul 170
Cambridge 164
Dublin 156
Hefei 138
Chandler 134
Wilmington 127
Florence 124
Beijing 121
Ann Arbor 90
Altamura 69
Lawrence 69
Princeton 43
Buffalo 41
Los Angeles 40
Ho Chi Minh City 34
Moscow 32
Jakarta 31
São Paulo 30
Medford 29
Shanghai 29
Paris 28
Dong Ket 27
Clifton 26
San Diego 26
Kent 25
Munich 23
Mumbai 22
Boston 20
Dallas 20
Barcelona 18
Hanoi 18
Melbourne 17
Phoenix 14
The Dalles 14
Frankfurt am Main 13
Milan 13
Bern 12
Boardman 12
Falls Church 12
Helsinki 12
Abidjan 11
Brussels 11
Brooklyn 10
Lappeenranta 10
London 10
New York 10
Belo Horizonte 9
Jacksonville 9
Redondo Beach 9
Yubileyny 9
Brasília 8
Chieri 8
Rome 8
Tokyo 8
Turku 8
Bengaluru 7
Chicago 7
Johannesburg 7
Tianjin 7
Turin 7
Amman 6
Donostia / San Sebastian 6
Naples 6
Padua 6
San Francisco 6
Can Tho 5
Guayaquil 5
Hangzhou 5
Quito 5
Redmond 5
Ribeirão Preto 5
Stockholm 5
Andover 4
Baghdad 4
Canicattì 4
Cotonou 4
Dearborn 4
Denver 4
Hải Dương 4
Istanbul 4
Kilburn 4
Montevideo 4
Nuremberg 4
Orem 4
Qingdao 4
Redwood City 4
Amsterdam 3
Baku 3
Cagliari 3
Canoas 3
Curitiba 3
Totale 6.360
Nome #
The Colony-Stimulating Factor-1 (CSF-1) Receptor Sustains ERK1/2 Activation and Proliferation in Breast Cancer Cell Lines. 353
Zoledronic acid impairs stromal reactivity by inhibiting M2-macrophages polarization and prostate cancer-associated fibroblasts. 341
Chromatin-associated CSF-1R binds to the promoter of proliferation-related genes in breast cancer cells. 315
Metabolic shift toward oxidative phosphorylation in docetaxel resistant prostate cancer cells. 308
Reprogramming of Amino Acid Transporters to Support Aspartate and Glutamate Dependency Sustains Endocrine Resistance in Breast Cancer 277
Mesenchymal to amoeboid transition is associated with stem-like features of melanoma cells 263
Targeting stromal-induced pyruvate kinase M2 nuclear translocation impairs OXPHOS and prostate cancer metastatic spread 239
The metabolic gene HAO2 is downregulated in hepatocellular carcinoma and predicts metastasis and poor survival 234
Cancer-associated fibroblasts promote prostate cancer malignancy via metabolic rewiring and mitochondrial transfer 212
Compartmentalized activities of the pyruvate dehydrogenase complex sustain lipogenesis in prostate cancer 211
Glucose Metabolic Reprogramming of ER Breast Cancer in Acquired Resistance to the CDK4/6 Inhibitor Palbociclib 204
Targeting the receptor tyrosine kinase RET in combination with aromatase inhibitors in ER positive breast cancer xenografts 203
Lactate modulates CD4 + T-cell polarization and induces an immunosuppressive environment, which sustains prostate carcinoma progression via TLR8/miR21 axis 188
Down-Regulation of SOX2 Underlies the Inhibitory Effects of the Triphenylmethane Gentian Violet on Melanoma Cell Self-Renewal and Survival 187
Stromal-induced downregulation of miR-1247 promotes prostate cancer malignancy 186
Fat and Furious: Lipid Metabolism in Antitumoral Therapy Response and Resistance 184
Metabolic reprogramming identifies the most aggressive lesions at early phases of hepatic carcinogenesis 179
miR-155 Drives Metabolic Reprogramming of ER+ Breast Cancer Cells Following Long-Term Estrogen Deprivation and Predicts Clinical Response to Aromatase Inhibitors. 177
Targeting the Metabolic Reprogramming That Controls Epithelial-to-Mesenchymal Transition in Aggressive Tumors 173
Selective anti-leukaemic activity of low-dose histone deacetylase inhibitor ITF2357 on AML1/ETO-positive cells 171
Senescent stroma promotes prostate cancer progression: The role of miR-210 169
Signaling pathways regulating redox balance in cancer metabolism 167
ERK5/BMK1 is indispensable for optimal colony-stimulating factor 1 (CSF-1)-induced proliferation in macrophages in a Src-dependent fashion. 161
Acetyl-CoA carboxylase 1 controls a lipid droplet-peroxisome axis and is a vulnerability of endocrine-resistant ER+ breast cancer 151
Lactate: A Metabolic Driver in the Tumour Landscape 151
Linking metabolic reprogramming to therapy resistance in cancer 148
Lactate supports cell-autonomous ECM production to sustain metastatic behavior in prostate cancer 147
Lysosomal lipid switch sensitises to nutrient deprivation and mTOR targeting in pancreatic cancer 146
Metabolic reprogramming in Nrf2-driven proliferation of normal rat hepatocytes 146
Succinate dehydrogenase subunit B mutations modify human neuroblastoma cell metabolism and proliferation 146
International multidisciplinary consensus on the integration of radiotherapy with new systemic treatments for breast cancer: European Society for Radiotherapy and Oncology (ESTRO)-endorsed recommendations 144
Integrating radiation therapy with targeted treatments for breast cancer: From bench to bedside 143
Safety of CDK4/6 inhibitors and concomitant radiation therapy in patients affected by metastatic breast cancer 140
Metabolic implication of tumor:stroma crosstalk in breast cancer. 135
RET in breast cancer: functional and therapeutic implications 134
GDNF-RET signaling in ER-positive breast cancers is a key determinant of response and resistance to aromatase inhibitors 132
Lactate rewires lipid metabolism and sustains a metabolic-epigenetic axis in prostate cancer 132
Sex difference in liver diseases: How preclinical models help to dissect the sex-related mechanisms sustaining NAFLD and hepatocellular carcinoma 131
FADS1/2 control lipid metabolism and ferroptosis susceptibility in triple-negative breast cancer 131
Nutrient Exploitation within the Tumor–Stroma Metabolic Crosstalk 131
Essential requirements for reporting radiation therapy in breast cancer clinical trials: An international multi-disciplinary consensus endorsed by the European Society for Radiotherapy and Oncology (ESTRO) 130
Targeting RET-interleukin-6 crosstalk to impair metastatic dissemination in breast cancer 129
Focal adhesion kinase (FAK) binds RET kinase via its FERM domain, priming a direct and reciprocal RET-FAK transactivation mechanism 128
Expression of activated VEGFR2 by R1051Q mutation alters the energy metabolism of Sk-Mel-31 melanoma cells by increasing glutamine dependence 123
Safety profile of trastuzumab-emtansine (T-DM1) with concurrent radiation therapy: a systematic review and meta-analysis 116
Thyroid hormone inhibits hepatocellular carcinoma progression via induction of differentiation and metabolic reprogramming 113
A novel phage display based platform for exosome diversity characterization 110
Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinase 98
Oxidative phosphorylation is a metabolic vulnerability of endocrine therapy and palbociclib resistant metastatic breast cancers 91
Targeting the receptor tyrosine kinase RET sensitizes breast cancer cells to tamoxifen treatment and reveals a role for RET in endocrine resistance 89
CD44 and SLC1A2 are commonly regulated but do not form a fusion transcript in ER+ breast cancer 80
In vivo imaging of the spatial heterogeneity of intratumoral acidosis (pH) as a marker of the metastatic phenotype in breast cancer 79
Safety profile of cyclin-dependent kinase (CDK) 4/6 inhibitors with concurrent radiation therapy: A systematic review and meta-analysis 77
Estrogen-dependent activation of TRX2 reverses oxidative stress and metabolic dysfunction associated with steatotic disease 54
Cardioprotection in patients with anthracycline-treated breast cancer: final analysis from the 2 × 2 randomized, placebo-controlled, double-blind SAFE trial 53
Targeting carbonic anhydrase IX/XII prevents the anti-ferroptotic effect of stromal lactic acid in prostate carcinoma 14
ESR1 Activating Mutations Confer Metabolic Vulnerabilities in ER+ Breast Cancer 14
Lead induces cell-autonomous proliferation and metabolic reprogramming of hepatocytes 11
Totale 8.999
Categoria #
all - tutte 23.885
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 23.885


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021494 0 0 0 0 0 69 49 48 85 147 48 48
2021/2022396 13 69 36 14 20 11 20 42 11 32 40 88
2022/2023778 62 190 44 41 49 137 96 35 69 9 27 19
2023/2024402 16 35 49 15 31 23 20 102 28 22 31 30
2024/20252.606 84 234 153 383 695 365 64 191 111 76 100 150
2025/20262.003 343 446 354 359 450 51 0 0 0 0 0 0
Totale 8.999